Kehoe Sean
Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK.
Best Pract Res Clin Obstet Gynaecol. 2006 Dec;20(6):985-1000. doi: 10.1016/j.bpobgyn.2006.06.006. Epub 2006 Aug 8.
Gynaecological cancers account for a significant amount of morbidity and mortality in the world, with varying incidences and outcomes depending on the country. These malignancies consist of vulval, vaginal, cervical, endometrial, fallopian and ovarian cancers, and account for between 10 and 15% of women's cancers. Although mainly a disease of post-menopausal women, when affecting younger women, fertility-related consequences exist. Therapeutic interventions for gynaecological cancers include surgery, chemotherapy and radiotherapy, with combination modalities often required. The basis for certain therapies are derived from appropriately conducted randomized clinical trial, whereas in some settings, therapy is based on clinical experience and intuition. This review will endeavour to focus on the evidence base, though inevitably, non-evidence based practice is unavoidable.
妇科癌症在全球导致了大量的发病和死亡，其发病率和预后因国家而异。这些恶性肿瘤包括外阴癌、阴道癌、宫颈癌、子宫内膜癌、输卵管癌和卵巢癌，占女性癌症的10%至15%。虽然主要是绝经后女性的疾病，但在影响年轻女性时，会存在与生育相关的后果。妇科癌症的治疗干预措施包括手术、化疗和放疗，通常需要联合使用多种方式。某些治疗方法的依据来自适当开展的随机临床试验，而在某些情况下，治疗则基于临床经验和直觉。本综述将致力于聚焦证据基础，不过不可避免地，非循证实践也难以避免。
